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Case report Multidrug resistant Kluyvera ascorbata septicemia 
in an adult patient: a case report
Shannon Moonah*, Kavita Deonarine and Clyde Freeman
Abstract
Introduction: Kluyvera ascorbata has become increasingly significant due to its potential to cause a wide range of 
infections, as well as its ability to transfer gene encoding for CTX-M- type extended spectrum B-lactamases (ESBLs) to 
other Enterobacteriaceae.
Case presentation: We report the case of a 64-year-old African-American male diagnosed with severe sepsis due to a 
multidrug resistant Kluyvera ascorbata, which was isolated from his blood. He was treated with meropenem and had a 
favorable outcome.
Conclusion: To the best of our knowledge, this is the first case report of a multidrug resistant Kluyvera ascorbata 
isolated from the blood in an adult patient with sepsis.
Introduction
Kluyvera ascorbata is a gram negative microorganism
belonging to the family Enterobacteriaceae. Although it
causes infections infrequently, it is responsible for caus-
ing a wide range of infections including severe sepsis
[1,2]. It is believed to be the source of genes encoding
CTX-M-type extended spectrum B-lactamases (ESBLs)
and it has the ability to transfer these genes to other
Enterobacteriacae [3]. Only three cases of K. ascorbata
i s o l a t e d  f r o m  t h e  b l o o d  o f  a d u l t  p a t i e n t s  h a v e  b e e n
reported [4-6]. We report what we believe to be the first
case of a multidrug resistant K. ascorbata isolated from
the blood of an adult patient with sepsis.
Case presentation
A 64-year-old African-American man with a past medical
history of hypertension, type 2 diabetes mellitus, bilateral
above knee amputation, prostate cancer post radical
prostatectomy in 1999, quadraparesis secondary to cervi-
cal spine fracture of C4, neurogenic bladder with an
indwelling suprapubic catheter and recurrent urinary
tract infections was transferred from a nursing home to
Howard University Hospital in June 2009 because of leth-
argy, fever and low blood pressure (BP). There was no
history of cough, chest pain, vomiting, diarrhea or head-
ache.
His admitting temperature was 101.4°F and blood pres-
sure 61/34 mmHg, which responded to intravenous fluid
boluses. His initial white blood count (WBC) was
14.4×109/L. His chest radiograph showed mild left lung
base ateclectasis, but the rest of the lung fields were clear.
Urinalysis showed large amounts of red cells, white cells
and numerous bacteria. He was admitted to the medical
intensive care unit (MICU) and started empirically on
vancomycin and levofloxacin.
Over the following five days his condition improved,
with normalization of his mental status, temperature, BP
and WBC. His initial blood culture bottle grew gram-
positive cocci, identified as Coagulase-negative staphylo-
cocci, thought to be a contaminant. Both urine cultures
were sterile.
He was transferred to the medical floor for further care.
24 hours later he developed a low grade temperature of
95.9°F, his BP decreased to a systolic of 75 mmHg and
WBC increased to 13×109/L. There was no change in his
mental status. He was given boluses of intravenous fluids.
Meropenem was immediately added to his antibiotic reg-
imen. A gram stain of his repeat blood culture revealed
gram negative rods which were later identified as K.
ascorbata. The isolate was susceptible to amikacin,
tobramycin and imipenem, but resistant to ampicillin,
piperacillin, cefazolin, cefuroxime, cefotaxime, ceftriax-
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one, ceftazidime, aztreonam, ciprofloxacin and levofloxa-
cin. Species identification and antimicrobial susceptibility
testing was performed using Microscan panels (Dade
Behring). He was placed on contact isolation and levo-
floxacin was discontinued. Over the next five days he
maintained a normal temperature, BP and WBC. Repeat
blood cultures and a urine culture were negative for
growth. He was discharged back to the nursing home
after 13 days of hospitalization for continued care.
Discussion
Kluyvera spp was first described in 1936 by Kluyver and
van Neil [7], but it was not until 1981 that it was defined
completely using molecular characterization [8]. Four
species are described: K. cryocrescens, K. ascorbata, K.
georgiana, and K. cochleae. K. ascobata causes a wide
range of infectious diseases in different age groups and of
varying severity [1,2,9].
Only three cases isolating K. ascobata from the blood
of adult patients with sepsis have been reported. In all
three cases the organism was susceptible to third genera-
tion cephalosporins (Table 1). To the best of our knowl-
edge, this is the first case report describing an isolate of
multidrug resistant K. ascorbata from the blood of an
adult patient with sepsis. The isolate was resistant to
third generation cephalosporins and fluoroquinolones. In
addition to its ability to cause severe sepsis, we also
report its multidrug resistant potential. This must be
considered when choosing appropriate antimicrobial
therapy. We believe that the prompt administration of a
carbapenem resulted in a favorable outcome for the
patient.
ESBLs are enzymes produced by certain types of bacte-
ria such as E. coli. They mediate resistance to extended-
spectrum cephalosporins (e.g. ceftriaxone) but do not
affect carbapenems (e.g. meropenem). Molecular and
genetic evidence indicates that CTX-M-type ESBLs
found in E. coli and other Enterobacteriaceace evolved
from chromosomal genes from K. ascobata. In the past
decade CTX-M enzymes have become the most preva-
Table 1: Summary of the four reported Kluyvera ascorbata cases isolated from the blood of adult patients
Ref. Age/sex Past medical 
history
Antimicrobial susceptibility Treatment Outcome
Susceptible Resistant
[4] 72/M Liver cirrhosis, 
Hepatocellular 
carcinoma,
Hepatitis C
Amoxicilin/Clavulanate
3rd generation 
cephalosporins
Aminoglycosides
Ciprofloxacin
Imipenem
Aztreonam
Ampicillin
Ticarcillin
Cephalothin
Cefuroxime
Cefotaxime Recovered
[5] 23/M Liver cirrhosis, 
Hepatitis B
Amoxicilin/
Clavulanate
Piperacillin
Ceftriaxone
Gentamicin
Ciprofloxacin
Ampicillin
Cefazolin
Ticarcillin
Ceftriaxone Recovered
[6] 57/F Colon 
adenocarcioma,
Chemotherapy,
Neutropenia
Aminoglycosides
3rd generation 
cephalosporins
Flouroquinolones
Ureidopenicillins
Ampicillin
Amoxicilin/
Clavulanate
2nd generation 
cephalosporins
Cotrimazole
Ceftazidime 
Amikacin
Expired
Present 
report
64/M Neurogenic 
bladder with an 
indwelling 
suprabupic 
catheter,
Recurrent urinary 
tract infections
Amikacin 
Tobramycin 
Imipenem
Ampicillin
Aztreonam
Ceftazidime
Cefotaxime
Cetftriaxone
Cefuroxime
Cefazolin
Ciprofloxacin
Levofloxacin
Piperacillin
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lent ESBLs and CTX-M producing E. coli is becoming a
major public health problem. This rise will result in the
narrowing of effective options to treat infections caused
by these organisms. There will likely be increased usage
of carbapenems, thus generating further selective pres-
sure for carbapenemases and carbepenem resistance in
the future [3,10-12].
Conclusion
K. ascorbata is an infrequent cause of infection, but can
result in severe sepsis. Clinicians should be aware of its
infectious and multidrug resistant potential as early and
appropriate treatment can result in recovery.
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